bioAffinity Technologies Highlights Lung Cancer Diagnostics at Event
bioAffinity Technologies, Inc. announced its participation in the Lung Cancer Initiative of North Carolina's Battle of the Blues event during National Lung Cancer Awareness Month. The company will highlight advancements in lung cancer diagnostics and therapies, focusing on its noninvasive CyPath® Lung test. The CyPath Lung test analyzes the lung microenvironment to detect potential lung cancer early, aiming to improve patient outcomes by enabling curative treatment when diagnosed at earlier stages.
Key Highlights
- bioAffinity Technologies to participate in the Lung Cancer Initiative of North Carolina's Battle of the Blues event.
- The event highlights advancements in lung cancer diagnostics and therapies.
- Company will present benefits of its noninvasive CyPath® Lung test.
- CyPath Lung analyzes lung microenvironment using flow cytometry, AI, and porphyrin TCPP.
- Test provides a binary result ('Likely' or 'Unlikely' for malignancy) to aid risk assessment.
- CyPath Lung has the potential to detect lung cancer earlier, including Stage 1A.
Price Impact
More from BIAF
bioAffinity Technologies Calls Special Meeting for Warrant, Share Authorization Votes
bioAffinity Technologies Reports Q2 Net Loss of $3.37M; Going Concern Doubt
bioAffinity Q2 Revenue $1.5M, Net Loss $3.4M; CyPath Lung Volume +216%
More in Business Update